Safeguard Financial’s Neurocrine Biosciences NBIX Stock Holding History

Safeguard Financial’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23	Closed	-$2K	–	379
2023 Q2	$2K	Buy	+23	New	+$2.25K	﹤0.01%	464

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Safeguard Financial's NBIX Position: Q3 2023 in Review

Safeguard Financial sold out of Neurocrine Biosciences (NBIX) in Q3 2023, closing a stake of 23 shares — an estimated $2K sold.

Safeguard Financial first reported a position in NBIX in Q2 2023 and held it in 1 quarter. The position peaked at $2K in Q2 2023. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

Safeguard Financial reported no remaining Neurocrine Biosciences position as of Q3 2023 after selling out during the quarter.
Safeguard Financial sold 23 Neurocrine Biosciences shares in Q3 2023, an estimated $2K.
Safeguard Financial first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 1 quarter.
Safeguard Financial's Neurocrine Biosciences position peaked at $2K in Q2 2023.
511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Safeguard Financial's 13F filing for Q3 2023, filed 30 Oct 2023.